These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 28301793)

  • 21. Is there a place for initial treatment with biological DMARDs in the early phase of RA?
    Nam JL; Emery P
    Best Pract Res Clin Rheumatol; 2013 Aug; 27(4):537-54. PubMed ID: 24315053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis.
    Feely MG; O'Dell JR
    Curr Opin Rheumatol; 2010 May; 22(3):316-20. PubMed ID: 20190639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biosimilar DMARDs: What Does the Future Hold?
    Araújo F; Gonçalves J; Fonseca JE
    Drugs; 2016 Apr; 76(6):629-37. PubMed ID: 26941025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-TNF biologics and their biosimilars in rheumatoid arthritis.
    Mok TC; Mok CC
    Expert Opin Biol Ther; 2024 Jul; 24(7):599-613. PubMed ID: 38766765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rheumatoid Arthritis.
    Sparks JA
    Ann Intern Med; 2019 Jan; 170(1):ITC1-ITC16. PubMed ID: 30596879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British Columbia.
    Dormuth CR; Fisher A; Carney G
    Pharmacoepidemiol Drug Saf; 2020 Jul; 29(7):796-802. PubMed ID: 31914214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis.
    Sen R; Riofrio M; Singh JA
    Expert Opin Drug Saf; 2024 Jun; 23(6):687-714. PubMed ID: 38695151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Biologicals and small molecules for rheumatoid arthritis].
    Blüml S
    Z Rheumatol; 2020 Apr; 79(3):223-231. PubMed ID: 32179964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of a biosimilar rituximab in biologic naïve patients with active rheumatoid arthritis.
    Roshique KK; Ravindran V
    Clin Rheumatol; 2015 Jul; 34(7):1289-92. PubMed ID: 26032432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.
    An Y; Liu T; He D; Wu L; Li J; Liu Y; Bi L; Zhou B; Lin C; He L; Liu X; Li X; Yang N; Zhang Z; Song H; Wei W; Liu J; Bi Y; Li Z
    Clin Rheumatol; 2017 Jan; 36(1):35-43. PubMed ID: 27709444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biosimilars for the management of rheumatoid arthritis: economic considerations.
    Gulácsi L; Brodszky V; Baji P; Kim H; Kim SY; Cho YY; Péntek M
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S43-52. PubMed ID: 26395836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues.
    Lapadula G; Ferraccioli GF
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S102-6. PubMed ID: 23078880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms.
    Ajeganova S; van Steenbergen HW; van Nies JA; Burgers LE; Huizinga TW; van der Helm-van Mil AH
    Ann Rheum Dis; 2016 May; 75(5):867-73. PubMed ID: 25972519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biosimilar drugs, myths and reality.
    Hernández-García C
    Reumatol Clin; 2014; 10(6):351-2. PubMed ID: 25037069
    [No Abstract]   [Full Text] [Related]  

  • 35. Current concepts in the management of rheumatoid arthritis.
    Tanaka Y
    Korean J Intern Med; 2016 Mar; 31(2):210-8. PubMed ID: 26932398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Era of biosimilars in rheumatology: reshaping the healthcare environment.
    Smolen JS; Goncalves J; Quinn M; Benedetti F; Lee JY
    RMD Open; 2019; 5(1):e000900. PubMed ID: 31245050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.
    Rannio T; Asikainen J; Kokko A; Hannonen P; Sokka T
    J Rheumatol; 2016 Apr; 43(4):699-706. PubMed ID: 26879355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rational approach to the prescription of anti-rheumatic drugs in rheumatoid arthritis: a product leaflet-based strategy in Italy.
    Perricone C; Castellucci A; Cafaro G; Calvacchi S; Bruno L; Dal Pozzolo R; Tromby F; Colangelo A; Gerli R; Bartoloni E
    Front Immunol; 2024; 15():1398314. PubMed ID: 38979406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rheumatoid arthritis: new monoclonal antibodies.
    Serio I; Tovoli F
    Drugs Today (Barc); 2018 Mar; 54(3):219-230. PubMed ID: 29771256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rheumatoid arthritis management of early disease.
    Nam JL
    Curr Opin Rheumatol; 2016 May; 28(3):267-74. PubMed ID: 26978129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.